Straumann Holding AG (SAUHY)
12.14
+0.14
(+1.17%)
USD |
OTCM |
Jun 25, 16:00
Straumann Enterprise Value: 19.11B for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 19.11B |
| June 24, 2024 | 18.88B |
| June 21, 2024 | 19.23B |
| June 20, 2024 | 19.20B |
| June 18, 2024 | 19.11B |
| June 17, 2024 | 18.95B |
| June 14, 2024 | 19.42B |
| June 13, 2024 | 19.84B |
| June 12, 2024 | 20.08B |
| June 11, 2024 | 19.87B |
| June 10, 2024 | 20.51B |
| June 07, 2024 | 20.27B |
| June 06, 2024 | 20.91B |
| June 05, 2024 | 20.44B |
| June 04, 2024 | 20.44B |
| June 03, 2024 | 20.14B |
| May 31, 2024 | 20.51B |
| May 30, 2024 | 20.35B |
| May 29, 2024 | 19.93B |
| May 28, 2024 | 20.13B |
| May 24, 2024 | 20.28B |
| May 23, 2024 | 20.44B |
| May 22, 2024 | 20.62B |
| May 21, 2024 | 20.43B |
| May 20, 2024 | 21.05B |
| Date | Value |
|---|---|
| May 17, 2024 | 20.87B |
| May 16, 2024 | 21.36B |
| May 15, 2024 | 21.32B |
| May 14, 2024 | 20.81B |
| May 13, 2024 | 20.60B |
| May 10, 2024 | 20.36B |
| May 09, 2024 | 20.84B |
| May 08, 2024 | 20.72B |
| May 07, 2024 | 20.32B |
| May 06, 2024 | 20.21B |
| May 03, 2024 | 20.24B |
| May 02, 2024 | 20.36B |
| May 01, 2024 | 21.08B |
| April 30, 2024 | 21.24B |
| April 29, 2024 | 23.91B |
| April 26, 2024 | 23.94B |
| April 25, 2024 | 23.41B |
| April 24, 2024 | 23.98B |
| April 23, 2024 | 23.71B |
| April 22, 2024 | 23.78B |
| April 19, 2024 | 23.36B |
| April 18, 2024 | 23.11B |
| April 17, 2024 | 23.86B |
| April 16, 2024 | 23.81B |
| April 15, 2024 | 23.89B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.215B
Minimum
Mar 19 2020
35.29B
Maximum
Nov 09 2021
20.39B
Average
19.67B
Median
Enterprise Value Benchmarks
| AC Immune SA | 280.41M |
| CRISPR Therapeutics AG | 2.642B |
| Addex Therapeutics Ltd | 6.723M |
| NLS Pharmaceutics Ltd | 8.04M |
| Molecular Partners AG | 50.90M |
Enterprise Value Related Metrics
| Earnings Yield | 1.41% |
| Operating Earnings Yield | 2.37% |
| Normalized Earnings Yield | 1.415 |